Peptides DB
Research-centric peptide and protocol reference hub
NatureNovember 11, 2026

Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide

Reported by Nature. Read the original →

What the story says

The headline reports that rare variants of the GLP1 receptor (GLP1R) reduce the effectiveness of semaglutide in promoting weight loss, while these variants do not have the same effect on tirzepatide.

Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • Semaglutide has 62 studies on file, 34 of them in humans, the newest published 2026.
  • Tirzepatide has 33 studies on file, 19 of them in humans, the newest published 2026.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.